{"id":499168,"date":"2020-07-28T18:14:01","date_gmt":"2020-07-28T18:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499168"},"modified":"2020-07-28T18:14:01","modified_gmt":"2020-07-28T18:14:01","slug":"adrenoleukodystrophy-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adrenoleukodystrophy-market-size-share-trends-epidemiology-forecast-till-2030_499168.html","title":{"rendered":"Adrenoleukodystrophy Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Adrenoleukodystrophy Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Adrenoleukodystrophy Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Adrenoleukodystrophy Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Adrenoleukodystrophy , historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total prevalent population of ALD in the 7MM in 2017 was 55,242<\/li>\n<li>The prevalent population of ALD in the US was 19,371 in 2017<\/li>\n<li>Among the EU5, Germany had the highest diagnosed prevalent population of ALD with 1,699 cases<\/li>\n<li>The highest diagnosed prevalence of ALD was in the United States in 2017 was 4,885<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/adrenoleukodystrophy-market\" target=\"_blank\">Adrenoleukodystrophy Market Size<\/a> in the United States in 2017 was USD 523.26 million<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Adrenoleukodystrophy , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Adrenoleukodystrophy epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Adrenoleukodystrophy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Adrenoleukodystrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adrenoleukodystrophy market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Adrenoleukodystrophy&nbsp;Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increased number of potential therapies in the pipeline<\/li>\n<li>Awareness about newborn screening programs<\/li>\n<li>Increase in the number of Childhood Cerebral Adrenoleukodystrophy (CALD) cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Adrenoleukodystrophy&nbsp;Emerging Therapies<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Lenti D: bluebird bio<\/li>\n<li>Leriglitazone: Minoryx Therapeutics, S.L.<\/li>\n<li>MD1003: MedDay Pharmaceuticals<\/li>\n<li>MGTA-456: Magenta Therapeutics<\/li>\n<li>OP-101: Orpheris Inc.<\/li>\n<li>SOM1201: SOM Biotech<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/adrenoleukodystrophy-market\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/ff6a23ccf8282e0bae5b04fb3cfd2268.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/adrenoleukodystrophy-market\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Adrenoleukodystrophy (ALD): Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">2.1. Total Market Share (%) Distribution of ALD in 2017<\/p>\n<p style=\"text-align: justify;\">2.2. Total Market Share (%) Distribution of ALD in 2030<\/p>\n<p style=\"text-align: justify;\">3. Adrenoleukodystrophy: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">3.1. Introduction<\/p>\n<p style=\"text-align: justify;\">3.2. Clinical aspects of ALD<\/p>\n<p style=\"text-align: justify;\">3.3. Causes of ALD<\/p>\n<p style=\"text-align: justify;\">3.4. Inheritance pattern of ALD<\/p>\n<p style=\"text-align: justify;\">3.5. ALD-Symptoms<\/p>\n<p style=\"text-align: justify;\">3.6. Pathogenesis and Pathophysiology of ALD<\/p>\n<p style=\"text-align: justify;\">3.7. Diagnosis<\/p>\n<p style=\"text-align: justify;\">3.7.1. ALD Newborn Screening<\/p>\n<p style=\"text-align: justify;\">3.7.2. Tools for evaluating Cerebral ALD<\/p>\n<p style=\"text-align: justify;\">3.7.3. Diagnostic algorithm<\/p>\n<p style=\"text-align: justify;\">3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan<\/p>\n<p style=\"text-align: justify;\">4. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">4.1. Key Findings<\/p>\n<p style=\"text-align: justify;\">4.2. Epidemiology Methodology<\/p>\n<p style=\"text-align: justify;\">4.3. KOL Views<\/p>\n<p style=\"text-align: justify;\">4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM<\/p>\n<p style=\"text-align: justify;\">5. United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.1. Assumptions and Rationale<\/p>\n<p style=\"text-align: justify;\">5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States<\/p>\n<p style=\"text-align: justify;\">5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States<\/p>\n<p style=\"text-align: justify;\">5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States<\/p>\n<p style=\"text-align: justify;\">5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States<\/p>\n<p style=\"text-align: justify;\">6. EU5 Epidemiology<\/p>\n<p style=\"text-align: justify;\">6.1. Germany Epidemiology<\/p>\n<p style=\"text-align: justify;\">6.1.1. Assumptions and Rationale<\/p>\n<p style=\"text-align: justify;\">6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany<\/p>\n<p style=\"text-align: justify;\">6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany<\/p>\n<p style=\"text-align: justify;\">6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany<\/p>\n<p style=\"text-align: justify;\">6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany<\/p>\n<p style=\"text-align: justify;\">6.2. France Epidemiology<\/p>\n<p style=\"text-align: justify;\">6.2.1. Assumptions and rationale<\/p>\n<p style=\"text-align: justify;\">6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France<\/p>\n<p style=\"text-align: justify;\">6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France<\/p>\n<p style=\"text-align: justify;\">6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France<\/p>\n<p style=\"text-align: justify;\">6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France<\/p>\n<p style=\"text-align: justify;\">6.3. Italy Epidemiology<\/p>\n<p style=\"text-align: justify;\">6.3.1. Assumptions and Rationale<\/p>\n<p style=\"text-align: justify;\">6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy<\/p>\n<p style=\"text-align: justify;\">6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy<\/p>\n<p style=\"text-align: justify;\">6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy<\/p>\n<p style=\"text-align: justify;\">6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy<\/p>\n<p style=\"text-align: justify;\">6.4. Spain Epidemiology<\/p>\n<p style=\"text-align: justify;\">6.4.1. Assumptions and Rationale<\/p>\n<p style=\"text-align: justify;\">6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain<\/p>\n<p style=\"text-align: justify;\">6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain<\/p>\n<p style=\"text-align: justify;\">6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain<\/p>\n<p style=\"text-align: justify;\">6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain<\/p>\n<p style=\"text-align: justify;\">6.5. United Kingdom Epidemiology<\/p>\n<p style=\"text-align: justify;\">6.5.1. Assumptions and Rationale<\/p>\n<p style=\"text-align: justify;\">6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">7. Japan Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.1. Assumptions and Rationale<\/p>\n<p style=\"text-align: justify;\">7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan<\/p>\n<p style=\"text-align: justify;\">7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan<\/p>\n<p style=\"text-align: justify;\">7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan<\/p>\n<p style=\"text-align: justify;\">7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan<\/p>\n<p style=\"text-align: justify;\">8. Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">8.1. Subtype-specific Treatment<\/p>\n<p style=\"text-align: justify;\">8.2. Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\">8.2.1. Recommendations for Treatment of X-linked ALD in the United States<\/p>\n<p style=\"text-align: justify;\">8.2.2. Adrenoleukodystrophy treatment: European Leukodystrophies Association<\/p>\n<p style=\"text-align: justify;\">8.3. Early intervention and long-term follow-up system for presymptomatic ALD patients in Japan<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">10.1. Lenti D: bluebird bio<\/p>\n<p style=\"text-align: justify;\">10.1.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">10.1.2. Regulatory Milestone<\/p>\n<p style=\"text-align: justify;\">10.1.3. Other Development Activities<\/p>\n<p style=\"text-align: justify;\">10.1.4. Clinical Development<\/p>\n<p style=\"text-align: justify;\">10.1.5. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">10.1.6. Advantages and Disadvantages<\/p>\n<p style=\"text-align: justify;\">10.1.7. Product Profile<\/p>\n<p style=\"text-align: justify;\">10.2. Leriglitazone: Minoryx Therapeutics, S.L.<\/p>\n<p style=\"text-align: justify;\">10.2.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">10.2.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">10.2.3. Other Development Activities<\/p>\n<p style=\"text-align: justify;\">10.2.4. Clinical Development<\/p>\n<p style=\"text-align: justify;\">10.2.5. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">10.2.6. Advantages and Disadvantages<\/p>\n<p style=\"text-align: justify;\">10.2.7. Product Profile<\/p>\n<p style=\"text-align: justify;\">10.3. MD1003: MedDay Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">10.3.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">10.3.2. Other Development Activities<\/p>\n<p style=\"text-align: justify;\">10.3.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">10.3.4. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">10.3.5. Advantages and Disadvantages<\/p>\n<p style=\"text-align: justify;\">10.3.6. Product Profile<\/p>\n<p style=\"text-align: justify;\">10.4. MGTA-456: Magenta Therapeutics<\/p>\n<p style=\"text-align: justify;\">10.4.1. Product Description<\/p>\n<p style=\"text-align: justify;\">10.4.2. Other Development Activities<\/p>\n<p style=\"text-align: justify;\">10.4.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">10.4.4. Clinical Trial Update<\/p>\n<p style=\"text-align: justify;\">10.4.5. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">10.4.6. Product Profile<\/p>\n<p style=\"text-align: justify;\">10.5. OP-101: Orpheris Inc.<\/p>\n<p style=\"text-align: justify;\">10.5.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">10.5.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">10.5.3. Other Development Activities<\/p>\n<p style=\"text-align: justify;\">10.5.4. Clinical Development<\/p>\n<p style=\"text-align: justify;\">10.5.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">10.6. SOM1201: SOM Biotech<\/p>\n<p style=\"text-align: justify;\">10.6.1. Product Description<\/p>\n<p style=\"text-align: justify;\">10.6.2. Other Development Activities<\/p>\n<p style=\"text-align: justify;\">10.6.3. Product Profile<\/p>\n<p style=\"text-align: justify;\">11. Failed Therapy<\/p>\n<p style=\"text-align: justify;\">11.1. NV1205: NeuroVia\/Archer Daniels Midland<\/p>\n<p style=\"text-align: justify;\">11.1.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">11.1.2. Other Development Activities<\/p>\n<p style=\"text-align: justify;\">11.1.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">11.1.4. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">11.1.5. Advantages and Disadvantages<\/p>\n<p style=\"text-align: justify;\">11.1.6. Product Profile<\/p>\n<p style=\"text-align: justify;\">12. Adrenoleukodystrophy (ALD): 7MM Market Analysis<\/p>\n<p style=\"text-align: justify;\">12.1. Key Findings<\/p>\n<p style=\"text-align: justify;\">12.2. Market Methodology<\/p>\n<p style=\"text-align: justify;\">12.3. Market Size of Adrenoleukodystrophy in the 7MM<\/p>\n<p style=\"text-align: justify;\">12.4. Market Size of Adrenoleukodystrophy by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\">13. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">14. United States<\/p>\n<p style=\"text-align: justify;\">14.1. United States Market Size<\/p>\n<p style=\"text-align: justify;\">14.1.1. Total Market size of Adrenoleukodystrophy in the United States<\/p>\n<p style=\"text-align: justify;\">14.1.2. Market Size of Adrenoleukodystrophy by Therapies in the US<\/p>\n<p style=\"text-align: justify;\">15. EU-5 countries<\/p>\n<p style=\"text-align: justify;\">15.1. Germany Market Size<\/p>\n<p style=\"text-align: justify;\">15.1.1. Total Market size of Adrenoleukodystrophy in Germany<\/p>\n<p style=\"text-align: justify;\">15.1.2. Market Size of Adrenoleukodystrophy by therapies in Germany<\/p>\n<p style=\"text-align: justify;\">15.2. France Market Size<\/p>\n<p style=\"text-align: justify;\">15.2.1. Total Market size of Adrenoleukodystrophy in France<\/p>\n<p style=\"text-align: justify;\">15.2.2. Market Size of Adrenoleukodystrophy by therapies in France<\/p>\n<p style=\"text-align: justify;\">15.3. Italy Market Size<\/p>\n<p style=\"text-align: justify;\">15.3.1. Total Market size of Adrenoleukodystrophy in Italy<\/p>\n<p style=\"text-align: justify;\">15.3.2. Market Size of Adrenoleukodystrophy by therapies in Italy<\/p>\n<p style=\"text-align: justify;\">15.4. Spain Market Size<\/p>\n<p style=\"text-align: justify;\">15.4.1. Total Market size of Adrenoleukodystrophy in Spain<\/p>\n<p style=\"text-align: justify;\">15.4.2. Market Size of Adrenoleukodystrophy by therapies in Spain<\/p>\n<p style=\"text-align: justify;\">15.5. United Kingdom Market Size<\/p>\n<p style=\"text-align: justify;\">15.5.1. Total Market size of Adrenoleukodystrophy in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">15.5.2. Market Size of Adrenoleukodystrophy by therapies in the UK<\/p>\n<p style=\"text-align: justify;\">16. Japan<\/p>\n<p style=\"text-align: justify;\">16.1. Japan Market Size<\/p>\n<p style=\"text-align: justify;\">16.1.1. Total Market size of Adrenoleukodystrophy in Japan<\/p>\n<p style=\"text-align: justify;\">16.1.2. Market Size of Adrenoleukodystrophy by therapies in Japan<\/p>\n<p style=\"text-align: justify;\">17. Market Drivers<\/p>\n<p style=\"text-align: justify;\">18. Market Barriers<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">19.1. Bibliography<\/p>\n<p style=\"text-align: justify;\">19.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\">20. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">21. Disclaimer<\/p>\n<p style=\"text-align: justify;\">22. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=adrenoleukodystrophy-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=adrenoleukodystrophy-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Adrenoleukodystrophy Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Adrenoleukodystrophy , historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/adrenoleukodystrophy-market-size-share-trends-epidemiology-forecast-till-2030_499168.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-499168","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=499168"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499168\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=499168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=499168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=499168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}